---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-019249"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2022-07-21T23:59:59+00:00"
generated_at: "2026-06-24T10:36:17.438312+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology reports record FY2022 revenue $49.1M (+20%); guides for 20% growth in FY2023

## Summary
- Record annual revenue $49.1M, up 20% YoY; Q4 revenue $12.9M, up 22% from $10.6M.
- FY2022 gross margin improved to 52% (from 48%); adjusted EBITDA $3.1M vs $2.1M.
- Operating income $607K for FY2022; cash $9.0M, no debt.
- Guidance: projects another year of top-line growth of ~20% for FY2023.
- CEO notes expanding ex-vivo services and computational discovery tools moving to preclinical development.

## SEC filing metadata
- accession: 0001628280-22-019249
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2022-07-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828022019249/0001628280-22-019249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828022019249/csbr8-k4302022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-019249
- JSON: https://secwatch.observer/filing/0001628280-22-019249.json
- Plain text: https://secwatch.observer/filing/0001628280-22-019249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.